X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Regeneron intends to update its full year 2022 financial guidance to reflect the Libtayo (cemiplimab) purchase during its second quarter 2022 earnings announcement in early August.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: $1,100.0 million Upfront Cash: $900.0 million
Deal Type: Acquisition July 01, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Under the terms announced today, Sanofi will transfer the rights to develop, commercialize and manufacture Libtayo (cemiplimab) entirely to Regeneron, on a worldwide basis, over the course of a defined transition period.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: $1,100.0 million Upfront Cash: $900.0 million
Deal Type: Collaboration June 02, 2022
Iran Expo
Not Confirmed
Contact Supplier
Details:
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
In the Phase 3 trial, safety was assessed in 697 patients, with a duration of exposure of 27 weeks (range: 9 days to 115 weeks) for the Libtayo group and 18 weeks (range: 18 days to 87 weeks) for the chemotherapy group.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
In Phase 3 trial, Libtayo, a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1, significantly improved overall survival in women with advanced cervical cancer after progression on chemotherapy, lowering the risk of death by 31%.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Protocol-specified interim analysis conducted by the Independent Data Monitoring Committee demonstrated that patients treated with Libtayo monotherapy had a significant increase in overall survival.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
Pexa-Vec (pexastimogene devacirepvec) is a vaccinia virus based oncolytic immunotherapy is being evaluated in combination with cemiplimab for the treatment of metastatic or unresectable renal cell carcinoma.
Lead Product(s): Pexastimogene devacirepvec,Cemiplimab
Therapeutic Area: Oncology Product Name: Pexa-Vec
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Under the agreement, GENESIS will commercialize the approved product of Regeneron, Libtayo (cemiplimab), which is a PD-1 inhibitor. It is used for the treatment of advanced basal cell carcinoma, cutaneous squamous cell carcinoma and non-small cell lung cancer.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2024
Details:
BL-8040 (motixafortide) is a CXCR4 inhibitor, which is being evaluated in combination with cemiplimab, and standard of care chemotherapies for the treatment of Pancreatic ductal adenocarcinoma.
Lead Product(s): Motixafortide,Cemiplimab,Gemcitabine
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent. It is being evaluated in combination with Libtayo (cemiplimab) for the treatment of advanced non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in phase 2 clinical trials in combination with Libtayo for the treatment of non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
Under the agreement, Medison will commercialize Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 08, 2024
Details:
THIO (6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development in combination with Libtayo (cemiplimab) to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
ISA101b (cemiplimab) is a PD-1 inhibitor vaccine drug candidate, which is currently being evaluated for the treatment of patients with advanced HPV16-positive oropharyngeal cancer.
Lead Product(s): ISA101b,Cemiplimab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
OR502 a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody. It is being evaluated for the treatment of advanced solid tumors.
Lead Product(s): OR502,Cemiplimab
Therapeutic Area: Oncology Product Name: OR502
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 15, 2023
Details:
The collaboration aims to evaluate ANK-101, a novel first-in-class anchored IL-12 immunotherapy in combination with Regeneron’s anti-PD-1 therapy, Libtayo (cemiplimab).
Lead Product(s): IL-12 Linked to Aluminum Hydroxide,Cemiplimab
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 13, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
Libtayo (cemiplimab) is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1. It block cancer cells from using the PD-1 pathway to suppress T-cell activation.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor (CPI) in patients with advanced Non-Small Cell Lung Cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
Under the agreement, Regeneron will supply Libtayo (cemiplimab), a PD-1 inhibitor, for the combination study of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate.
Lead Product(s): ONM-501,Cemiplimab
Therapeutic Area: Oncology Product Name: ONM-501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 06, 2023
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
E-602 is a first-in-class glyco-immune checkpoint inhibitor developed by Palleon from the EAGLE (Enzyme Antibody Glyco-Ligand Editing) oncology platform and is being developed in combination with Libtayo (cemiplimab) in patients with advanced cancers.
Lead Product(s): E-602,Cemiplimab
Therapeutic Area: Oncology Product Name: E-602
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
The Company intends to use the proceeds from the offering to fund the ongoing clinical trials of THIO including THIO-101 (6-Thio-2'-deoxyguanosine), pre-clinical development of second-generation of telomere targeting compounds, and other research and development activities.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 27, 2023
Details:
The Company intends to use the net proceeds to fund the ongoing clinical trials of THIO, including THIO-101 (6-thio-2'-deoxyguanosine) and pre-clinical development of second-generation of telomere targeting compounds.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 24, 2023
Details:
E-602 is a first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. It is being investegated for lung cancer and melanoma.
Lead Product(s): E-602,Cemiplimab
Therapeutic Area: Oncology Product Name: E-602
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
HST-1011 is an investigational orally bioavailable, selective, small molecule allosteric inhibitor of CBL-B, an E3 ubiquitin protein ligase critically involved in immune cell response, yielding the activation and propagation of a targeted anti-tumor immune response.
Lead Product(s): HST-1011,Cemiplimab
Therapeutic Area: Oncology Product Name: HST-1011
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
Libtayo (cemiplimab-rwlc) is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells to block cancer cells. It is approved for advanced PD-L1 positive non-small cell lung cancer, in combinationwith chemotherapy.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
GRWD5769 is the first-in-class ERAP1 inhibitor, being investigated as alone and in combination with libtayo for the treatment of advanced solid tumours.
Lead Product(s): GRWD5769,Cemiplimab
Therapeutic Area: Oncology Product Name: GRWD5769
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Libtayo (cemiplimab-rwlc) is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells to block cancer cells.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
Under the terms of the CRADA, Sensei will collaborate with the NCI to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody and to assess the mechanism of action of SNS-101 in combination with novel therapeutic modalities.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2023
Details:
Grey Wolf Therapeutics will use the net proceeds to Support Advancement of Lead Candidate, ERAP1 Inhibitor GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023 and support the continued development of the company's first-of-its-kind immuno-oncology approaches.
Lead Product(s): GRWD5769,Cemiplimab
Therapeutic Area: Oncology Product Name: GRWD5769
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Ventures
Deal Size: $49.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 26, 2023
Details:
The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sensei Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
Libtayo (cemiplimab), is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC), in sequential administration with Regeneron’s anti-PD1 therapy, Libtayo® (cemiplimab).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
THIO-101 is designed to evaluate THIO’s potential immune system activation effects in NSCLC patients by administering THIO in advance of administration of Regeneron’s anti-PD1 therapy, Libtayo® (cemiplimab).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
RP1 (vusolimogene oderparepvec) is designed to treat more immune responsive tumor types. The encoded GALV-GP R- protein enhances the tumor killing ability of the virus and increases immunogenic cell death.
Lead Product(s): Vusolimogene Oderparepvec,Cemiplimab
Therapeutic Area: Oncology Product Name: RP1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2022
Details:
RP1 (vusolimogene oderparepvec) is designed to treat more immune responsive tumor types. The encoded GALV-GP R- protein enhances the tumor killing ability of the virus and increases immunogenic cell death.
Lead Product(s): Vusolimogene Oderparepvec,Cemiplimab
Therapeutic Area: Oncology Product Name: RP1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 07, 2022
Details:
ISA101b immunotherapy targets human papillomavirus type 16 (HPV16) positive cancers. It induces strong and specific immune responses to the HPV16 virus, and (re-)establishes a powerful and targeted T-cell immune response against infected and/or cancerous cells and tissues.
Lead Product(s): ISA101b,Cemiplimab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Alaunos intends to use the net proceeds from the offering to fund the continued development of the product candidates in its pipeline, and for working capital, capital expenditures and general corporate purposes.
Lead Product(s): Ad-RTS-hIL-12,Veledimex,Cemiplimab
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $15.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2022
Details:
Libtayo (cemiplimab) is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells and was invented using Regeneron's proprietary VelocImmune® technology.
Lead Product(s): Cemiplimab,Undisclosed
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
